Literature DB >> 30087070

Efficacy and safety of ultrasound-guided totally implantable venous access ports via the right innominate vein in adult patients with cancer: Single-centre experience and protocol.

Xingwei Sun1, Jin Xu2, Rui Xia2, Caishan Wang3, Ziyang Yu3, Jian Zhang1, Xuming Bai4, Yong Jin5.   

Abstract

BACKGROUND: Totally implantable venous access ports (TIVAPs) are widely used and are an essential tool in the efficient delivery of chemotherapy. This study aimed to evaluate the feasibility and safety of implantation of ultrasound (US)-guided TIVAPs via the right innominate vein (INV) for adult patients with cancer.
METHODS: This study retrospectively reviewed the medical records of 283 adult patients with cancer who underwent US-guided INV puncture for TIVAPs between September 2015 and September 2017. It also analysed the technical success rate, operation time, and short-term and long-term surgical complications.
RESULTS: Technical success was achieved in all patients (100%). The mean operation time was 28.31 ± 7.31 min (range: 23-39 min), and the puncture success rate for the first attempt was 99.30% (281/283). Minor complications included artery puncture during the operation in one patient, but no pneumothorax was encountered. The mean TIVAP time was 304.16 ± 42.54 days (range: 38-502 days). The rate of postoperative complications was 2.83% (8/283), including poor healing of the incision in one patient, catheter-related infections in three patients, port thrombosis in one patient, and fibrin sheath formation in three patients; no catheter malposition, pinch-off syndrome, catheter fracture, or other serious complications were observed.
CONCLUSIONS: TIVAPs are widely employed for chemotherapy. The present study found that the novel approach of using US-guided INV puncture to implant TIVAPs in adult patients with cancer is both short-termly feasible and safe for long-term central venous access.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Cancer; Innominate vein; Totally implantable venous access ports; Ultrasonography

Mesh:

Year:  2018        PMID: 30087070     DOI: 10.1016/j.ejso.2018.07.048

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Ultrasound-guided totally implantable venous access ports via the right innominate vein: a new approach for patients with breast cancer.

Authors:  Liang Xu; Wenming Qin; Weiwei Zheng; Xingwei Sun
Journal:  World J Surg Oncol       Date:  2019-11-25       Impact factor: 2.754

2.  Perioperative and Postoperative Complications of Supraclavicular, Ultrasound-Guided, Totally Implantable Venous Access Port via the Brachiocephalic Vein in Adult Patients: A Retrospective Multicentre Study.

Authors:  Zepeng Yu; Xingwei Sun; Xuming Bai; Wei Ding; WeiDong Wang; Liang Xu; Wenming Qin; Ling Wen; Yong Jin
Journal:  Ther Clin Risk Manag       Date:  2021-02-04       Impact factor: 2.423

3.  Case report: Bilateral pleural effusion secondary to late migration of a tunneled central venous catheter in a patient affected by high risk neuroblastoma.

Authors:  Tommaso Domenico D'Angelo; Giorgio Persano; Alessandro Crocoli; Cristina Martucci; George Koshy Parapatt; Gian Luigi Natali; Alessandro Inserra
Journal:  Front Pediatr       Date:  2022-08-04       Impact factor: 3.569

4.  Comparison between ultrasound-guided TIVAD via the right innominate vein and the right internal jugular vein approach.

Authors:  Xingwei Sun; Xuming Bai; Jiaofeng Shen; Ziyang Yu; Zhixiang Zhuang; Yong Jin
Journal:  BMC Surg       Date:  2019-12-11       Impact factor: 2.102

Review 5.  Forty years after the first totally implantable venous access device (TIVAD) implant: the pure surgical cut-down technique only avoids immediate complications that can be fatal.

Authors:  Adriana Toro; Elena Schembari; Emanuele Gaspare Fontana; Salomone Di Saverio; Isidoro Di Carlo
Journal:  Langenbecks Arch Surg       Date:  2021-06-09       Impact factor: 3.445

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.